Calliditas Therapeutics A... (CALT)
NASDAQ: CALT
· Real-Time Price · USD
40.00
-0.04 (-0.10%)
At close: Sep 20, 2024, 10:00 PM
Calliditas Therapeutics AB (publ) Revenue Breakdown
| Period Ending | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|
| Royalty Income Revenue | 36.76M | 2.29M |
| Royalty Income Revenue Growth | +1507.26% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|
| Asia Revenue | 91.44M | 286.68M |
| Asia Revenue Growth | -68.10% | n/a |
| Europe Revenue | 39.61M | 143.96M |
| Europe Revenue Growth | -72.48% | n/a |
| Se Revenue | n/a | n/a |
| Se Revenue Growth | n/a | n/a |
| Us Revenue | 1.08B | 372.25M |
| Us Revenue Growth | +189.01% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 419.82M | 342.17M | 293.17M | 259.17M | 268.62M | 239.77M | 272.92M | 187.14M | 172.18M | 142.43M | 151.71M | 95.37M | 84.37M | 58.78M | 63.88M | 41.04M | 18.8M | 18.01M | 23.79M | 10.29M | 19M | 9.8M | 44.77M | 31.34M | 18.55M | 38.49M | 40.57M | 17.53M | 15.47M | 11.09M |
| Selling, General, and Administrative Revenue Growth | +22.69% | +16.71% | +13.12% | -3.52% | +12.03% | -12.14% | +45.84% | +8.69% | +20.89% | -6.12% | +59.07% | +13.04% | +43.54% | -7.99% | +55.67% | +118.32% | +4.38% | -24.30% | +131.08% | -45.80% | +93.82% | -78.11% | +42.86% | +68.99% | -51.81% | -5.14% | +131.47% | +13.28% | +39.53% | n/a |
| Research and Development Revenue | 120.72M | 150.61M | 106.68M | 179.91M | 88.99M | 126.65M | 102.24M | 102.88M | 96.29M | 113.34M | 100.29M | 92.1M | 75.02M | 90.08M | 73.99M | 64.89M | 48.39M | 54.11M | 41.71M | 46.19M | 31.19M | 30.74M | 34.17M | 24.05M | 10M | 31.03M | 27.16M | 7.77M | 9.52M | 7.24M |
| Research and Development Revenue Growth | -19.85% | +41.19% | -40.70% | +102.17% | -29.74% | +23.88% | -0.62% | +6.84% | -15.05% | +13.01% | +8.90% | +22.76% | -16.72% | +21.74% | +14.03% | +34.10% | -10.57% | +29.72% | -9.69% | +48.07% | +1.47% | -10.04% | +42.06% | +140.55% | -67.78% | +14.27% | +249.38% | -18.33% | +31.47% | n/a |
| Sales and Marketing Revenue | 252.99M | 240.15M | 198.54M | 170.5M | 191.47M | 167.22M | 191.89M | 116.14M | 113.27M | 93.9M | 70.64M | 31.17M | 58.37M | 19.43M | -13.96M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | +5.35% | +20.96% | +16.45% | -10.95% | +14.50% | -12.85% | +65.23% | +2.53% | +20.63% | +32.93% | +126.61% | -46.60% | +200.46% | -239.13% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |